Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
Status:
Completed
Trial end date:
2020-03-05
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the addition of 90Y Zevalin to BEAM
chemotherapy (carmustine, etoposide, cytarabine, and melphalan) and rituximab is more
effective than the combination of BEAM and rituximab alone in patients with lymphoma who
receive a stem cell transplant.